Title
Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential
Date Issued
21 November 2020
Access level
open access
Resource Type
editorial
Author(s)
Krause P.R.
Fleming T.R.
Ellenberg S.S.
Henao-Restrepo A.M.
Krause P.R.
Fleming T.R.
Alejandria M.M.
Bhargava B.
Ellenberg S.S.
Halloran E.
Henao-Restrepo A.M.
Longini I.
Miranda Montoya M.C.
Roses M.
Sommerfelt H.
University of Pennsylvania
Publisher(s)
Lancet Publishing Group
Start page
1611
End page
1613
Volume
396
Issue
10263
Language
English
OCDE Knowledge area
EpidemiologÃa
Enfermedades infecciosas
Scopus EID
2-s2.0-85096100956
PubMed ID
Source
The Lancet
ISSN of the container
01406736
Sponsor(s)
SSE reports personal fees for DMC service from Merck, Marinus, the Bill & Melinda Gates Foundation, Bristol Myers Squibb, and Novartis; consulting fees from Urogen, Alkermes, Shionogi, Insmed, Innovative Science Solutions, Janssen, and Mallinkrodt; lecture fees from Sanofi; and grants paid to the University of Pennsylvania from AbbVie. PRK, TRF, and AMH-R declare no competing interests. The views expressed in this Comment do not necessarily reflect those of the US Food and Drug Administration.
Sources of information:
Directorio de Producción CientÃfica
Scopus